Pterisolic acid B
Pterisolic acid B (J19) is an effective Nrf2 activator. we have also identified a more potent natural product analogue J19-1, J19-1 shows significant cytoprotective effect against cisplatin-induced cytotoxicity in HKC cells.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Phys Chem Chem Phys.2018, 20(23):15986-15994
Int J Mol Sci.2023, 24(5):4505.
Acta Pharm Sin B.2024, 14(4):1772-1786.
Appl. Sci. 2021, 11(23),11099.
J Cell Mol Med.2024, 28(16):e70015.
Biomol Ther (Seoul).2024, 32(5):546-555.
Ecol Evol.2022, 12(11):e9459.
Adv. Anim. Vet. Sci.2024, 12(5):986-993.
Sci Rep.2023, 13(1):21690.
J Basic Clin Physiol Pharmacol.2016, 27(1):1-8
Related and Featured Products
Sci. Rep.-UK, 2016, 6,19231.
Pterisolic Acid B is a Nrf2 Activator by Targeting C171 within Keap1-BTB Domain[Pubmed:
PMC4725373]
The use of chemoprotective agents to minimize the side effects of the chemotherapy, primarily via activation of the Nrf2 pathway, is an emerging research field, which has attracted broad attention from both academia and pharmaceutical industry.
METHODS AND RESULTS:
Through high-throughput chemical screens we have disclosed that Pterisolic acid B (J19), a naturally occuring diterpenoid, is an effective Nrf2 activator. We have also identified a more potent natural product analogue J19-1 by semisynthesis and the subsequent biochemical evaluations revealed that J19-1 activates the Nrf2 pathway by covalently modifying Cys171 of keap1, which inhibits Nrf2 degradation mediated by Keap1-Cul3 complexes.
CONCLUSIONS:
Ultimately, we have demonstrated that J19-1 shows significant cytoprotective effect against cisplatin-induced cytotoxicity in HKC cells.
